Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus Erythematosus: A Monocentric Experience and Review of the Current Literature

Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus Erythematosus: A Monocentric Experience and Review of the Current Literature

Refractory cutaneous manifestations constitute a significant unmet need in patients with cutaneous lupus (CLE), even in the setting of systemic lupus erythematosus (SLE) with otherwise good control of inflammatory manifestations. Anifrolumab, an anti-interferon I receptor monoclonal antibody has rec...

Full description

Bibliographic Details
Main Authors: Giovanni Paolino, Giuseppe A. Ramirez, Chiara Calabrese, Luca Moroni, Vittoria Giulia Bianchi, Enrica P. Bozzolo, Santo Raffaele Mercuri, Lorenzo Dagna
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Biomedicines
Subjects:
anifrolumab
lupus
cutaneous
discoid
CLA-IGA
Online Access:https://www.mdpi.com/2227-9059/11/11/2904

Internet

https://www.mdpi.com/2227-9059/11/11/2904

Similar Items